Dr. Ismaell Massalha, MD, MHA, is a board-certified radiation oncologist and senior physician at the Radiation Oncology Unit, Ziv Medical Center, Israel, where he leads the Head and Neck radiation oncology service. He received his MD from Universität Ulm, Germany, completed oncology training at Soroka Medical Center, and holds a Master of Health Administration from Ben-Gurion University. He is currently a PhD researcher in Medical Bioinformatics at Ben-Gurion University, focusing on clinical decision-support systems in oncology. His clinical and research interests include precision oncology, real-world evidence, radiation oncology, treatment toxicity, cancer survivorship, immunotherapy-related adverse events, and machine-learning models for risk prediction in cancer patients. His academic work includes studies on immune checkpoint inhibitor toxicity, perioperative FLOT in gastric/GEJ cancer, SBRT in frail patients, MRI surveillance in SCLC, and AI-based early detection of sepsis in oncology patients. Dr. Massalha is a member of ASCO, ESMO, the Israeli Medical Association, and the Israel Society for Clinical Oncology and Radiotherapy. His recognitions include the Clalit ROMAH Award, Roche Excellence Grant, Israeli Oncology Excellence Award, and D4H Best Poster Award for oncology data-science research.
Dr. Ismaell Massalha, MD, MHA, is a board-certified radiation oncologist and senior physician at the Radiation Oncology Unit, Ziv Medical Center, Israel, where he leads the Head and Neck radiation oncology service. He received his MD from Universität Ulm, Germany, completed oncology training at Soroka Medical Center, and holds a Master of Health Administration from Ben-Gurion University. He is currently a PhD researcher in Medical Bioinformatics at Ben-Gurion University, focusing on clinical decision-support systems in oncology. His clinical and research interests include precision oncology, real-world evidence, radiation oncology, treatment toxicity, cancer survivorship, immunotherapy-related adverse events, and machine-learning models for risk prediction in cancer patients. His academic work includes studies on immune checkpoint inhibitor toxicity, perioperative FLOT in gastric/GEJ cancer, SBRT in frail patients, MRI surveillance in SCLC, and AI-based early detection of sepsis in oncology patients. Dr. Massalha is a member of ASCO, ESMO, the Israeli Medical Association, and the Israel Society for Clinical Oncology and Radiotherapy. His recognitions include the Clalit ROMAH Award, Roche Excellence Grant, Israeli Oncology Excellence Award, and D4H Best Poster Award for oncology data-science research.